VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
Summary
VERAXA Biotech says it has established in vitro proof-of-concept for its BiTAC-ADC platform. The company says the data support a tumor-restricted activation approach that could improve precision and reduce off-tumor toxicity in antibody drug conjugates. VERAXA plans to use the BIO International Convention 2026 to open partnering discussions around both its BiTAC-ADC and BiTAC-TCE platforms. The company positions the technology as a differentiated therapeutic engine for future cancer programs and partner-led development.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected